Academic Journal

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study

التفاصيل البيبلوغرافية
العنوان: Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study
المؤلفون: Elisabeth Blüthner, Ulrich-Frank Pape, Frank Tacke, Sophie Greif
المصدر: Nutrients; Volume 15; Issue 8; Pages: 1949
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2023
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: quality of life, SF-36, SBS-QoL TM, teduglutide, glucagon-like peptide-2, parenteral nutrition, stool frequency, sleep disturbances
جغرافية الموضوع: agris
الوصف: Background: Quality of life (QoL) data of chronic intestinal failure (cIF) patients treated with the GLP-2 analogue teduglutide are scarce. This study aims to analyze QoL changes over time in teduglutide-treated patients and compare the results to a matched non-treated cIF control group in a real-world setting. Methods: QoL data (SF-36 and SBS-QoLTM) were obtained from adult cIF patients being treated with teduglutide and compared to previously collected QoL data from a PNLiver trial (DRKS00010993), during which patients had been therapy naive. The dataset was then extended by a pairwise matched control group (non-teduglutide-treated PNLiver trial patients) and follow-up data from this group were collected accordingly. Results: Median teduglutide treatment duration and the follow-up period of controls were both 4.3 years. SBS-QoLTM subscales and the SBS-QoLTM sum score showed significant improvements over time in teduglutide-treated patients, as well as for the SF-36 physical and mental component summary scores (all p < 0.02), while non-treated patients showed no significant changes in any of the mentioned scores. Significant differences of QoL changes between treated and non-treated patients were seen for both SF-36 summary scores (p = 0.031 and 0.012). Conclusions: We herein demonstrate for the first time that QoL significantly improved during teduglutide treatment in SBS-cIF patients in a real-world setting compared to individually matched non-treated SBS-cIF patients, indicating relevant clinical benefits.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
Relation: Clinical Nutrition; https://dx.doi.org/10.3390/nu15081949
DOI: 10.3390/nu15081949
الاتاحة: https://doi.org/10.3390/nu15081949
Rights: https://creativecommons.org/licenses/by/4.0/
رقم الانضمام: edsbas.EB13EA01
قاعدة البيانات: BASE